Skip to nav Skip to content

COVID-19 AdvisoryVisitors limited to only one parent/caregiver at all clinics and no siblings allowed. Learn more.

Blood Cancers

Image of cellLeukemia tumors employ a number of tricks to stop T cells from working. A protein molecule on the surface of cancer cells connects with a protein receptor on T cells to dampen T cells’ natural ability to combat cancer. In essence, the cancer protein sends a highly effective “shut off” signal to T cells, enabling the cancer cells to escape T cell-mediated killing. Our work takes a piece of the existing T cell protein, the part that reads the “shut off” signal, and fuses it to a piece from another protein that gives the T cells a “boost.” This creates a chimeric protein, or immunomodulatory fusion protein (IFP), that tells the T cell to ignore the “shut off” signal and instead, ramp up its activity.

Specifically, our team has been developing a new CD200R-based IFP to improve in vivo anti-tumoral T-cell function against acute myeloid leukemia (AML). CD200R/CD200 is a cellular receptor/ligand pair that has been identified as being able to mediate the message pathways between tumor cells and T cells. We used our modified T cells to treat immunocompetent mice with disseminated leukemia and achieved dramatic improvement in T cell survival rate, from 40% survival without IFP to 89% survival when treated with CD200R-CD28 modified T cells. We have also evaluated the CD200R-CD28 IFP in human T cells for future clinical trials and demonstrated enhanced anti-tumor function as well as increased eradication of patient AML cells.

By clicking “Accept All Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in marketing efforts. For more information, see Website Privacy.

Accept All Cookies